Abdyldaev R A, Kruglova G V
Ter Arkh. 1987;59(6):43-6.
A comparative analysis of the long-term results of treatment of 709 lymphosarcoma patients has shown that the main prognostic factor determining the patients's survival was a morphological tumor type. Therapeutic policy with regard to prognostic factors was proposed for lymphosarcomas. Lymphosarcomas of a high degree of malignancy required intensive therapy using cycle polychemotherapy, whereas monochemotherapy was recommended for patients with lymphosarcomas of a low degree of malignancy. Treatment of stage I-II mediastinal lymphosarcomas should be very intensive and prolonged.
对709例淋巴肉瘤患者的长期治疗结果进行的比较分析表明,决定患者生存的主要预后因素是肿瘤的形态学类型。针对淋巴肉瘤提出了基于预后因素的治疗策略。高度恶性的淋巴肉瘤需要采用周期多药化疗进行强化治疗,而低度恶性淋巴肉瘤患者则推荐采用单一化疗。I-II期纵隔淋巴肉瘤的治疗应非常强化且疗程延长。